Kilitch Drugs Limited, a leading pharmaceutical company specializing in high-quality parenterals, oral solids and effervescents, announced its unaudited financial results for the half year ended September 30, 2025.

The company reported a Profit After Tax of 10.30 crore in H1 FY26, an 18.1 per cent increase compared to Rs. 8.72 crore in H1 FY25. The growth in profitability was supported by improved operational efficiencies, better product mix and consistent demand across key markets.

Total income for the period stood at Rs. 7101.28 crore, registering a 14.23 per cent YoY growth from Rs. 88.66 crore in H1 FY25. The company continued to strengthen its presence in domestic and international markets, driven by sustained orders for its parenteral range and increasing traction in oral solids and effervescent formulations.

Commenting on the company's Q2FY26 performance, Mukund Mehta, Chairman and Managing Director, Kilitch Drugs Limited, said, "Our HIFY26 results reflect steady and broad-based growth across our key markets and product segments. The continued demand for our effervescent, injectable formulation including oral solid dosage formulations, coupled with operational efficiency, has supported our profitability. We remain committed to sustainable growth, and long-term value creation for our stakeholders.

With a healthy order pipeline and steady demand outlook, the company expects business momentum to remain positive in the second half of FY26.”